Investigating how ergosterol peroxide can selectively inhibit aggressive breast cancer
Official title: Validating the mode of action of ergosterol peroxide as a selective breast cancer inhibitor
Funded at Universidad Central Del Caribe · NIH-11060936 · Data updated 2026-11-12
This study is looking at how a natural compound from fungi, called ergosterol peroxide, can help fight triple-negative breast cancer by killing cancer cells without harming normal cells, with the hope of creating a new treatment option for patients facing this tough type of cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Universidad Central Del Caribe NIH-funded |
| Lab location | 1 site (Bayamon, United States) |
| Project start | April 15, 2022 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $117,029 |
| NIH project number | 5R16GM145488-04 |
| Project ID | NIH-11060936 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer, particularly younger women under 40 years old.
✕Less likely to help
Patients with other types of breast cancer or those who do not have a diagnosis of breast cancer may not benefit from this research.
What this research studies
This research focuses on understanding how ergosterol peroxide, a natural compound found in fungi, can effectively target and inhibit triple-negative breast cancer (TNBC) cells while sparing normal cells. The study aims to identify the specific mechanisms through which ergosterol peroxide induces cell death in TNBC, which is known for its aggressive nature and poor prognosis. By exploring the compound's effects on tumor growth and its ability to induce oxidative stress and apoptosis in cancer cells, the research seeks to develop a new targeted therapy for patients suffering from this challenging cancer subtype.
Why it matters
Potential benefit: If successful, this research could lead to a new, effective treatment option for patients with triple-negative breast cancer, potentially improving survival rates and reducing treatment-related side effects.
How similar studies have gone: Previous research has shown promise in using natural compounds like ergosterol peroxide for cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
-
Universidad Central Del Caribe
Bayamon, United States Active
Researchers
- Principal investigator: Martinez, Michelle M — Universidad Central Del Caribe
- Study coordinator: Martinez, Michelle M
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.